Published • loading... • Updated
New drug combination could delay the progression of advanced prostate cancer
The Phase III AMPLITUDE trial showed niraparib with standard therapy reduced cancer growth risk by 37% overall and 48% in patients with BRCA1/BRCA2 mutations.
Summary by Medical Xpress
6 Articles
6 Articles
New drug combination could delay the progression of advanced prostate cancer
A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.
·United States
Read Full ArticleNew hope for prostate patients as study shows treatment can slow cancer growth
Patients with certain genetic mutations were found to have the most benefit from the combination of drugs. Patients with a certain form of aggressive prostate cancer could benefit from a new combination of drugs which slow cancer growth, according to a new study. Academics said their findings support wider use of genetic testing for cancer patients after their study showed that patients with certain genetic mutations appeared to benefit more tha…
Coverage Details
Total News Sources6
Leaning Left1Leaning Right0Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium